Innovative Stroke Therapy Neuravi's flagship product, the EmboTrap®II Revascularization Device, demonstrates cutting-edge technology in stroke treatment, with CE marking and availability in Europe. Its investigational status in the US suggests potential for broader market expansion as approval processes progress.

Strategic Acquisition Now part of Johnson & Johnson through acquisition, Neuravi benefits from enhanced global reach and resources, presenting opportunities to leverage Johnson & Johnson's extensive distribution and sales channels to accelerate product adoption worldwide.

Research and Collaboration Focus The company invests in the Neuravi Thromboembolic Initiative (NTI), fostering collaboration between engineers, clinicians, and researchers. This positions Neuravi as a leader in ongoing innovation, opening avenues for partnerships and customized solutions in neurovascular care.

Funding and Growth Potential With $17 million in funding and recent acquisitions, Neuravi has the financial backing to scale clinical trials and expand its product portfolio, offering sales teams opportunities to align with a growing company focused on breakthrough stroke therapies.

Global Market Presence Although small with 2-10 employees, Neuravi's presence in the European market and ongoing US investigational use creates opportunities to connect with hospital systems, clinical networks, and regional distributors seeking advanced neurovascular devices.